This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R)

  • 79-83% in normal testosterone (T) range (FDA requirement 75%)
  • No patient elevated beyond normal range
  • Androxal's impact on sperm concentration meets FDA non-inferiority threshold compared to placebo
  • Potential key points of differentiation from gels

THE WOODLANDS, Texas, March 27, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism. Results for the Intent-to-Treat population met both co-primary endpoints mandated by the FDA. The Intent-to-Treat population included all men randomized in the study whether or not they completed the study.

151 subjects were randomized into the study, 38 on placebo and 113 on Androxal.

Testosterone Endpoint

The primary testosterone endpoint required that 75% of the subjects in the drug arm exhibit a 24 hour average total testosterone in the normal range (300–1040 ng/dL) at the end of 12 weeks of treatment. Any subjects that dropped out of the trial before the 24 hour assessment were to have their last observation carried forward. Men who dropped out before their first visit following the randomization visit carried their baseline observation forward.

All 113 men in the Androxal arm were included in the Intent-to-Treat population. Six of the subjects discontinued prematurely. Four of these subjects had no visit after the randomization visit and their baseline data was carried forward.

After six weeks of dosing, men were allowed to up-titrate if their morning testosterone was below 300 ng/dL. No up-titrations were allowed after that point. 21 of the 113 subjects in the Androxal arm up-titrated from the 12.5 to the 25 mg dose. Some of the men that were not up-titrated exhibited only a marginal response to the 12.5 mg dose.

79% of the Intent-to-Treat Androxal subjects exhibited 24 hour average testosterone levels in the normal range. Importantly, not a single subject exhibited any testosterone assessment at any time that was above the normal range. This included any of the individual assessments made during the 24 hour sampling. This finding is a particularly important safety assessment for the FDA during their review of any treatment for hypogonadism.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs